Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Purpose
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Condition
- Psoriasis
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Male or female adult ≥ 18 years of age; - Diagnosis of chronic plaque-type - Patient with 2-10% BSA - Physician Global Assessment of 2 or greater - Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks
Exclusion Criteria
- ˂2 or >10% BSA - PGA <2 - Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab <24weeks
Study Design
- Phase
- Phase 4
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Intervention Model Description
- open label
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Open Label Enstilar |
once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira |
|
Recruiting Locations
Psoriasis Treatment Center of Central New Jersey
East Windsor 8354649, New Jersey 5101760 08520
East Windsor 8354649, New Jersey 5101760 08520
More Details
- Status
- Recruiting
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Detailed Description
30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for 4 weeks followed by QOD for 12 weeks.